Association of vitiligo with endocrine autoimmune diseases: literature review

Vitiligo is a dermatological disease characterized by focal disappearance of the melanin pigment on the skin and mucous membranes of a person. Despite the variety of proposed hypotheses for the development of this pathology, the central role belongs to the autoimmune mechanism of melanocyte damage.

Analysis of the results of numerous international studies confirms a pronounced tendency towards an increase in the prevalence of endocrine autoimmune diseases among patients with vitiligo compared to the general population. Such diseases include, first of all, autoimmune thyroiditis, Graves' disease, type I diabetes mellitus and autoimmune adrenal insufficiency. Some studies confirm a high frequency of vitiligo combination with multiendocrine autoimmune syndromes.

This review is aimed at systematizing the available scientific literature on the frequency of occurrence and characteristics of associated autoimmune endocrine disorders in individuals suffering from vitiligo.

1. Pathak GN, Tan IJ, Bai G, Dhillon J, Rao BK. Vitiligo: From mechanisms of disease to treatable pathways. Skin Health Dis. 2024;4(6):e460. Published 2024 Sep 30. doi: https://doi.org/10.1002/ski2.460

2. Seong SH, Oh SH. Up-and-Coming Drugs for the Treatment of Vitiligo. Ann Dermatol. 2024;36(4):197-208. doi: https://doi.org/10.5021/ad.24.038

3. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571-592. doi: https://doi.org/10.1159/000506103

4. Migayron L, Boniface K, Seneschal J. Vitiligo, From Physiopathology to Emerging Treatments: A Review. Dermatol Ther (Heidelb). 2020;10(6):1185-1198. doi: https://doi.org/10.1007/s13555-020-00447-y

5. Gill L, Zarbo A, Isedeh P, Jacobsen G, Lim HW, Hamzavi I. Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol. 2016;74(2):295-302. doi: https://doi.org/10.1016/j.jaad.2015.08.063

6. Troshina EA, Volnukhin VA, Petrov VA, et al. Ter Arkh. 2020;92(10):88-96. Published 2020 Nov 24. doi: https://doi.org/10.26442/00403660.2020.10.000736

7. Kussainova A, Kassym L, Akhmetova A, et al. Vitiligo and anxiety: a systematic review and meta-analysis. PLoS One. 2020;15(11):e0241445. doi: https://doi.org/10.1371/journal.pone.0241445

8. Ezzedine K, Diallo A, Léauté-Labrèze C, et al. Pre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo. Br J Dermatol. 2012;167(3):490-495. doi: https://doi.org/10.1111/j.1365-2133.2012.11002.x

9. Sun Y, Kan X, Zheng R, Hao L, Mao Z and Jia Y (2023) Hashimoto’s thyroiditis, vitiligo, anemia, pituitary hyperplasia, and lupus nephritis—A case report of autoimmune polyglandular syndrome type III C + D and literature review. Front. Pediatr. 11:1062505. doi: https://doi.org/10.3389/fped.2023.1062505

10. Gatta E, Maltese V, Cimino E, et al. Evaluation of a large set of patients with Autoimmune Polyglandular Syndrome from a single reference centre in context of different classifications. J Endocrinol Invest. 2024;47(4):857-864. doi: https://doi.org/10.1007/s40618-023-02200-6

11. Husebye ES, Anderson MS, Kämpe O. Autoimmune Polyendocrine Syndromes. N Engl J Med. 2018;378(12):1132-1141. doi: https://doi.org/10.1056/NEJMra1713301

12. Dahir AM, Thomsen SF. Comorbidities in vitiligo: comprehensive review. Int J Dermatol. 2018;57(10):1157-1164. doi: https://doi.org/10.1111/ijd.14055

13. Bouayad A, Benzekri L. Thyroid autoimmunity in relation to HLA-DRB1 and HLA-DQB1 polymorphism in nonsegmental vitiligo: a crosssectional- study. Am J Transl Res. 2024;16(2):524-530. Published 2024 Feb 15. doi: https://doi.org/10.62347/LDYE8203].

14. Nuralieva NF, Yukina MYu, Troshina EA, Zhukova OV, Petrov VA, Volnukhin VA. Frequent association of vitiligo with endocrine autoimmune diseases: primary data in a Russian cohort of adult patients. // Bulletin of the Russian State Medical University. - 2022. - No. 5. - P. 68-74. doi: https://doi.org/10.24075/vrgmu.2022.055

15. Lee JH, Ju HJ, Seo JM, et al. Comorbidities in Patients with Vitiligo: A Systematic Review and Meta-Analysis. J Invest Dermatol. 2023;143(5):777-789.e6. doi: https://doi.org/10.1016/j.jid.2022.10.021

16. Abuhalimeh RM, Alshmrani LS, Abdullah N, et al. Updates on the Association Between Vitiligo and Thyroid Diseases: A Systematic Review. Cureus. 2024;16(9):e69697. Published 2024 Sep 19. doi: https://doi.org/10.7759/cureus.69697

17. Chivu AM, Bălășescu E, Pandia LD, Nedelcu RI, Brînzea A, Turcu G, Antohe M, Ion DA. Vitiligo—Thyroid Disease Association: When, in Whom, and Why Should It Be Suspected? A Systematic Review. Journal of Personalized Medicine. 2022;12(12):2048. doi: https://doi.org/10.3390/jpm12122048

18. Sandru F. et al. Spectrum of thyroid antibodies in vitiligo-associated autoimmunity. Endocr. Pract. 2021

19. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Published 2021 Mar 29. doi: https://doi.org/10.1136/bmj.n71

20. Ashraf A, Azfar NA, Chaudhry A, Rasul A, Irfan M, Liaqat Z. Frequency of positive thyroid peroxidase antibody levels in patients of generalized vitiligo. J Pak Assoc Dermatol. 2021;31:583-587

21. Gong Q, Li X, Gong Q, Zhu W, Song G, Lu Y. Hashimoto’s thyroiditis could be secondary to vitiligo: the possibility of antigen crossover and oxidative stress between the two diseases. Arch Dermatol Res. 2016;308(4):277-281. doi: https://doi.org/10.1007/s00403-016-1641-z

22. Huang J, Jiang L, Hu Y, et al. Association of Vitiligo With Autoimmune Disorders: A Bidirectional Two-Sample and Summary- Based Mendelian Randomization Study. J Cosmet Dermatol. 2025;24(6):e70211. doi: https://doi.org/10.1111/jocd.70211

23. Kassem R, Baum S, Barzilai A. Vitiligo. In: Shoenfeld, Y., Cervera, R., Espinosa, G., Gershwin, M.E. (eds) Autoimmune Disease Diagnosis. Springer, Cham. doi: https://doi.org/10.1007/978-3-031-69895-8_69

24. Bae JM, Lee JH, Yun JS, Han B, Han TY. Vitiligo and overt thyroid diseases: A nationwide population-based study in Korea. J Am Acad Dermatol. 2017;76(5):871-878. doi: https://doi.org/10.1016/j.jaad.2016.12.034

25. Chang HC, Lin MH, Huang YC, Hou TY. The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol. 2019;81(6):1442-1445. doi: https://doi.org/10.1016/j.jaad.2019.06.022

26. Lee JH, Ju HJ, Seo JM, et al. Comorbidities in Patients with Vitiligo: A Systematic Review and Meta- Analysis. J Invest Dermatol. 2023;143(5):777-789.e6. doi: https://doi.org/10.1016/j.jid.2022.10.021

27. AL-smadi K, Imran M, Leite-Silva VR, Mohammed Y. Vitiligo: A Review of Aetiology, Pathogenesis, Treatment, and Psychosocial Impact. Cosmetics. 2023;10(3):84. doi: https://doi.org/10.3390/cosmetics10030084

28. Raveendra L, Hemavathi RN, Rajgopal S. A Study of Vitiligo in Type 2 Diabetic Patients. Indian J Dermatol. 2017;62(2):168-170. doi: https://doi.org/10.4103/ijd.IJD_360_16

29. Zhao L, Hu M, Li L. Identifying the Genetic Associations Between Diabetes Mellitus and the Risk of Vitiligo. Clin Cosmet Investig Dermatol. 2024;17:2261-2271. Published 2024 Oct 13. doi: https://doi.org/10.2147/CCID.S480199

30. Clemente Hernández B, Muelas Rives I, Gracia Cazaña T, Álvarez Salafranca M, Poblador-Plou B, Laguna-Berna C, Moreno Juste A, Gimeno-Miguel A, Gilaberte Y. Comorbidities Associated with Vitiligo: Results from the EpiChron Cohort. Journal of Clinical Medicine. 2025; 14(2):432. doi: https://doi.org/10.3390/jcm14020432

31. Chang WL, Ko CH. The Role of Oxidative Stress in Vitiligo: An Update on Its Pathogenesis and Therapeutic Implications. Cells. 2023;12(6):936. Published 2023 Mar 19. doi: https://doi.org/10.3390/cells12060936

32. Białczyk A, Wełniak A, Kamińska B, et al. Oxidative Stress and Potential Antioxidant Therapies in Vitiligo: A Narrative Review. Mol Diagn Ther 2023;27:723–739. doi: https://doi.org/10.1007/s40291-023-00672-z

33. Lyu C and Sun Y (2022) Immunometabolism in the pathogenesis of vitiligo. Front. Immunol. 13:1055958. doi: https://doi.org/10.3389/fimmu.2022.1055958

34. Chiarella P. Vitiligo susceptibility at workplace and in daily life: the contribution of oxidative stress gene polymorphisms. biomed dermatol 2019;3:5. doi: https://doi.org/10.1186/s41702-019-0043-1

35. Meyer G, Neumann K, Badenhoop K, Linder R. Increasing prevalence of Addison’s disease in German females: health insurance data 2008-2012. Eur J Endocrinol. 2014;170(3):367-373. Published 2014 Feb 4. doi: https://doi.org/10.1530/EJE-13-0756

36. Van Geel N, Speeckaert M, Brochez L, Lambert J, Speeckaert R. Clinical profile of generalized vitiligo patients with associated autoimmune/autoinflammatory diseases. J Eur Acad Dermatol Venereol. 2014;28(6):741-746. doi: https://doi.org/10.1111/jdv.12169

37. Petrov V.A., Zhukova O.V., Volnukhin V.A., Troshina E.A., Yukina M.Yu., et al. Vitiligo associated with autoimmune adrenal insufficiency. // RMJ. - 2023. - No. 10. — P.39-42.

38. Saleem K, Azim W. Association of vitiligo with other autoimmune disorders. Diabetes Case Rep. 2016;1(3):1000114. doi: https://doi.org/10.4172/2572-5629.1000114

39. Vitiligo: clinical guidelines / Ministry of Health of the Russian Federation. - 2023. - 96 p.

40. Olisova O. Yu., Kayumova L. N., Eremin P. S., Gilmutdinova I. R., Pinegin V. B., et al. Comparative review of traditional and promising methods of vitiligo treatment. // Bulletin of Restorative Medicine. - 2024; - Vol. 23. - No. 6. - Pp. 90-99. doi: https://doi.org/10.38025/2078-1962-2024-23-6-90-99